Dr. David Feinberg to discuss Geisinger's pioneering efforts
The event will be held February 21st at the Convene Cira Centre in Philadelphia, Pennsylvania.
Dr. Feinberg’s presentation, entitled “Geisinger’s Path Forward with Precision Medicine,” will explore key learnings from the health system’s extensive work in genomic research, providing a roadmap for large-scale DNA sequencing for other institutions. His session will deliver insights into the early successes of precision medicine at Geisinger, and how the organization’s big database will be used to introduce population health initiatives while also guiding personalized care that clinicians deliver to individual patients daily.
Geisinger is internationally recognized for its pioneering efforts to bring precision health into daily clinical care. Dr. Feinberg will discuss strategies in genomic medicine, how Geisinger’s MyCode Community Health Initiative has signed up more than 180,000 participants and is returning clinical results to patients who are at high risk for early onset cancers (breast, ovarian, colon), early onset cardiac events (heart attack, stroke) and several other potentially preventable conditions.
“We have this genetic information, along with clinical information, along with 20 years’ worth of electronic health records data for four generations of families and we're returning results to our patients – what is now called precision medicine,” says Dr. Feinberg. “But what Geisinger is doing is really anticipatory medicine. We are taking a population-approach to genomics and returning medically actionable results. By doing so, it allows us to treat our patients before they get sick and helps prevent life-threatening disease. This is the future of healthcare.”
The Precision Medicine for Hospital CEOs Conference is an educational, one-day summit for hospital and health system C-Suite administrators to introduce successful implementations in the major areas of precision medicine: oncology, pharmacogenomics, infectious disease, population analytics based on big data.
One of the nation’s most innovative health services organizations, Geisinger serves more than 1.5 million patients in Pennsylvania and New Jersey. The system includes 13 hospital campuses, a nearly 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. Geisinger is known for its focus on caring and innovative programs including the ProvenCare® best-practice approach to maximize quality, safety and value; ProvenHealth Navigator® advanced medical home; Springboard Health® population health program to improve the health of an entire community; ProvenExperience™ to provide refunds to patients unhappy with their care experience; and Geisinger’s MyCode® Community Health Initiative, the largest healthcare system-based precision health project in the world. With more than 215,000 volunteer participants enrolled, MyCode is conducting extensive research and returning medically actionable results to participants. A physician-led organization, with approximately 32,000 employees and more than 1,800 employed physicians, Geisinger leverages an estimated $12.7 billion positive annual impact on the Pennsylvania and New Jersey economies. Repeatedly recognized nationally for integration, quality and service, Geisinger has a long-standing commitment to patient care, medical education, research and community service. For more information, visit www.geisinger.org, or connect with us on Facebook, Instagram, LinkedIn and Twitter.